. 2022 Dec 3;22:521. doi: 10.1186/s12872-022-02928-8

Table 1.

The study inclusion and exclusion criteria

inclusion criteria	exclusion criteria
• age > 18 years, stable IHD lasting for at least 2 years • intake of Atorvastatin 20 mg or Rosuvastatin 10 mg for at least 2 years.	• diabetes different than type 2, • acute coronary incident/intervention in last 3 months, • acute infection, • thyroid diseases, history of neoplasm, immunodeficiency disorders, • patients after surgical procedures in previous 3 months, • pregnancy, • intake of: insulin, statins of another type or dose than Atorvastatin 20 mg or Rosuvastatin 10 mg, non- steroid anti-inflammatory drugs (NSAID) and/or steroids, fibrates, fibrinolytics.

inclusion criteria

exclusion criteria

• age > 18 years, stable IHD lasting for at least 2 years

• intake of Atorvastatin 20 mg or Rosuvastatin 10 mg for at least 2 years.

• diabetes different than type 2,

• acute coronary incident/intervention in last 3 months,

• acute infection,

• thyroid diseases, history of neoplasm, immunodeficiency disorders,

• patients after surgical procedures in previous 3 months,

• pregnancy,

• intake of: insulin, statins of another type or dose than Atorvastatin 20 mg or Rosuvastatin 10 mg, non- steroid anti-inflammatory drugs (NSAID) and/or steroids, fibrates, fibrinolytics.